Get in touch with one of our Xperts.
We are proud to have supported TAHO Pharmaceuticals Ltd. (TAHO) in the successful submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TAH3311, the first orodispersible film formulation of apixaban. This submission marks an important milestone for TAHO and a promising advancement in the field of anticoagulant therapy. TAH3311 has continue reading…
3D-PharmXchange is proud to be a partner in the BRECISE project (Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement), a five-year initiative co-funded by the Innovative Health Initiative (IHI) under Horizon Europe. The project brings together more than 30 public and private organizations across Europe with the shared goal of accelerating the continue reading…
3D-PharmXchange is proud to announce its collaboration with Antleron in the Living Factory 4.0 project. Antleron is a Leuven-based R&D company that develops custom bioprocess solutions for cell & gene therapy applications, with a focus on personalized and digital manufacturing. The Living Factory 4.0, supported by the CrossRoads program, aims to revolutionize the development and production of continue reading…
© 3D-PharmXchange 2025